Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03639714 · ClinicalTrials.gov registry record · Phase 1

A Study of a Personalized Neoantigen Cancer Vaccine

A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Gritstone bio.

Completed
Registry status
Phase 1
Development phase
29
Enrollment target
11
Study locations

NCT03639714 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that has completed, run by Gritstone bio. The registered enrollment target is 29 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03639714, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, has completed, sponsored by Gritstone bio.

COMPLETED
Registry status
Phase 1
Development phase
29 participants
Enrollment target
11
Study locations

Study Summary

The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.

Conditions Studied

Non-Small Cell Lung Cancer Colorectal Cancer Urothelial Carcinoma Gastroesophageal Adenocarcinoma

Interventions

  • BIOLOGICAL nivolumab
  • BIOLOGICAL ipilimumab
  • BIOLOGICAL GRT-C901
  • BIOLOGICAL GRT-R902

Study Locations (11)

New York

  • Memorial Sloan Kettering Cancer Center - New York
  • Columbia University Medical Center - New York

Arizona

  • Mayo Clinic Arizona - Phoenix

Florida

  • Mayo Clinic - Jacksonville

Illinois

  • The University of Chicago - Chicago

Minnesota

  • Mayo Clinic - Rochester

Ohio

  • The Ohio State University Comprehensive Cancer Center - Columbus

Tennessee

  • Tennessee Oncology - Nashville

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 29 participants
Start Date 2019-02-13
Est. Completion 2022-11-10
Phase Phase 1

Sponsor

Gritstone bio

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03639714

The ClinicalTrials.gov registry entry for NCT03639714 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Gritstone bio, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which nivolumab is the first listed.

NCT03639714 reports 11 study locations spanning 10 distinct geographic areas - top geographies include New York, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT03639714 about?

NCT03639714 is a clinical study titled "A Study of a Personalized Neoantigen Cancer Vaccine". The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colore...

What is the current status of trial NCT03639714?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2019-02-13. Estimated completion is 2022-11-10.

What conditions does trial NCT03639714 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Carcinoma, Gastroesophageal Adenocarcinoma.

What interventions are being tested in trial NCT03639714?

The interventions under investigation include: nivolumab (BIOLOGICAL), ipilimumab (BIOLOGICAL), GRT-C901 (BIOLOGICAL), GRT-R902 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03639714?

This trial is sponsored by Gritstone bio, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03639714 being conducted?

This trial has 11 study locations across Arizona, Florida, Illinois, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Colorectal Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.